NASDAQ:INBX • US45720N1037
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INHIBRX BIOSCIENCES INC (INBX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-22 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-05-15 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2025-03-18 | Citizens Capital Markets | Reiterate | Market Perform -> Market Perform |
| 2025-01-22 | JMP Securities | Reiterate | Market Perform -> Market Perform |
| 2024-07-23 | JMP Securities | Initiate | Market Perform |
| 2024-01-23 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-11-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-23 | JMP Securities | Maintains | Outperform -> Outperform |
| 2023-05-10 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-08 | JMP Securities | Maintains | Market Outperform |
| 2023-03-07 | Credit Suisse | Reiterate | Outperform |
| 2022-11-08 | Credit Suisse | Maintains | Outperform |
| 2022-10-05 | Evercore ISI Group | Maintains | Outperform |
| 2022-08-09 | Credit Suisse | Maintains | Outperform |
| 2022-03-02 | JMP Securities | Maintains | Market Outperform |
| 2021-11-10 | Credit Suisse | Maintains | Outperform |
| 2021-11-02 | JMP Securities | Maintains | Market Outperform |
| 2021-09-21 | JMP Securities | Initiate | Market Outperform |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.19M -69.71% | 1.8M -17.81% | 200K -88.89% | 1.326M 563.00% | -100.00% | 344.61M | 99.596M -71.10% | 131.83M 32.36% | 190.97M 44.86% | 237.02M 24.11% | |
| EBITDA YoY % growth | -127.89M -69.71% | -218.03M -70.48% | -329.163M -50.97% | -91.676M 72.15% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -129.12M -68.65% | -219.221M -69.78% | -331.448M -51.19% | -141.017M 57.45% | -98.049M 30.47% | -21.33M 78.25% | -23.772M -11.45% | -1.702M 92.84% | 41.259M 2,523.61% | 73.571M 78.32% | |
| Operating Margin | -5,895.89% | -12,178.94% | -165,724.00% | -10,634.77% | N/A | -6.19% | -23.87% | -1.29% | 21.60% | 31.04% | |
| EPS YoY % growth | -3.62 -68.37% | -5.03 -38.95% | 118.11 2,448.11% | -9.19 -107.78% | -4.85 47.17% | -2.81 42.20% | -1.16 58.55% | -0.08 92.98% | 1.53 1,975.00% | 2.70 76.67% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.12 31.44% | -1.23 56.03% | -1.14 38.47% | -1.22 46.41% | -1.26 40.49% | -0.94 24.03% | -0.88 22.58% | -0.58 52.92% | -0.41 67.15% | -0.48 49.07% | -0.36 59.14% | -0.23 59.75% |
| Revenue Q2Q % growth | -100.00% | -100.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -34.833M 30.23% | -22.101M 52.13% | -24.235M 11.51% | -25.594M 24.31% | -26.118M 25.02% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
6 analysts have analysed INBX and the average price target is 12.24 USD. This implies a price decrease of -79.91% is expected in the next year compared to the current price of 60.92.
INHIBRX BIOSCIENCES INC (INBX) will report earnings on 2026-03-23.
The consensus EPS estimate for the next earnings of INHIBRX BIOSCIENCES INC (INBX) is -2.12 USD and the consensus revenue estimate is 0 USD.
The expected long term growth rate for INHIBRX BIOSCIENCES INC (INBX) is 1400.52%.